Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1… Grant US-11497756-B2 United States of America 15 Nov 2022
Formulations comprising heterocyclic protein kinase inhibitors Grant US-11471456-B2 United States of America 18 Oct 2022
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer Grant US-11034710-B2 United States of America 15 Jun 2021
Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors Grant US-10875864-B2 United States of America 29 Dec 2020